- Chanelle is based in Galway, Ireland
- This transaction follows Exponent’s investment in BBI Group
- Exponent is a private equity firm with offices in London, Dublin and Amsterdam
Exponent has agreed to invest in Chanelle Pharma, a generic drug manufacturer, from its founder Michael H Burke.
Galway, Ireland-based Chanelle employs over 700 people in Ireland, UK, Europe and Jordan. It provides services such as research and product development and the registration and production of generic human and veterinary pharmaceuticals.
The firm will work with “Chanelle’s management team to strengthen its global presence and invest in its capabilities,” said David McGovern, partner at Exponent.
Chanelle is Exponent’s sixth flagship investment in Ireland.
“We see tremendous opportunity in the development pipeline and look forward to bringing new products to market, as well as continuing to invest in research and development in the years to come,” said James Gunton, partner at Exponent.
This transaction follows Exponent’s investment in BBI Group.
Exponent is a private equity firm with offices in London, Dublin and Amsterdam. The firm invests in companies headquartered across Europe (UK, Ireland, Benelux and Nordics) with enterprise values between €150 million to €500 million.
No financial terms of the transaction were disclosed.